In conclusion, adropin can reduce atherosclerosis in ApoE-/-/Enho-/- mice through non-lipid-regulating pathway, by inhibiting EndMT via the TGF-β/Smad2/3 signaling pathway. This evidence concerns the gene SMAD2 and atherosclerosis.